Profit and Loss Results Results Snapshot
Figures in Cr
Standalone - Profit And Loss Results
Mar'25
Mar'24
Mar'23
Mar'22
Mar'21
Mar'20
Profit And Loss Analysis Highlights
Net Sales
YoY Growth in year ended Mar 2025 is 32.48% vs 29.17% in Mar 2024
Operating Profit (PBDIT) excl Other Income
YoY Growth in year ended Mar 2025 is 37.69% vs 11.71% in Mar 2024
Interest
YoY Growth in year ended Mar 2025 is 21.67% vs 90.48% in Mar 2024
Profit After Tax
YoY Growth in year ended Mar 2025 is -28.34% vs 62.66% in Mar 2024
Compare Profit and Loss Results of Astrazeneca Phar
Figures in Cr
standalone - Profit And Loss Results
Change(INR)
Change(%)
No of Months
12
12
Operating Income
1,716.00
4,381.00
-2,665.00
-60.83%
Less :Inter divisional transfers
0.00
0.00
0.00
0%
Less: Excise
0.00
0.00
0.00
0%
Net Sales
1,716.00
4,381.00
-2,665.00
-60.83%
Expenditure (Ex Depriciation)
Stock Adjustments
-332.00
-126.00
-206.00
-163.49%
Raw Materials Consumed
1,295.00
2,133.00
-838.00
-39.29%
Power & Fuel Cost
5.00
99.00
-94.00
-94.95%
Employee Cost
257.00
782.00
-525.00
-67.14%
Operating Expenses
18.00
275.00
-257.00
-93.45%
General and Administration Expenses
-1.00
-1.00
0.00
0.00%
Selling and Distribution Expenses
93.00
293.00
-200.00
-68.26%
Cost of Software developments
0.00
0.00
0.00
0%
Miscellaneous Expenses
13.00
119.00
-106.00
-89.08%
Expenses Capitalised
0.00
0.00
0.00
0%
Total Expenditure
1,462.00
3,758.00
-2,296.00
-61.10%
Operating Profit (PBDIT) excl Other Income
253.00
623.00
-370.00
-59.39%
Other Income
40.00
142.00
-102.00
-71.83%
Operating Profit (PBDIT)
294.00
765.00
-471.00
-61.57%
Interest
1.00
112.00
-111.00
-99.11%
Profit before Depriciation and Tax
293.00
652.00
-359.00
-55.06%
Depreciation
39.00
224.00
-185.00
-82.59%
Profit Before Taxation & Exceptional Items
253.00
427.00
-174.00
-40.75%
Exceptional Income / Expenses
0.00
0.00
0.00
0%
Profit Before Tax
156.00
427.00
-271.00
-63.47%
Provision for Tax
40.00
110.00
-70.00
-63.64%
Profit After Tax
115.00
317.00
-202.00
-63.72%
Extraordinary Items
0.00
0.00
0.00
0%
Adj to Profit After Tax
0.00
0.00
0.00
0%
Profit Balance B/F
578.00
1,695.00
-1,117.00
-65.90%
Profit Available for appropriations
693.00
2,012.00
-1,319.00
-65.56%
Appropriations
693.00
2,012.00
-1,319.00
-65.56%
Equity Dividend (%)
1600%
30%
1,570.00
Earnings Per Share
46.3
16.95
29.35
173.16%
Profit And Loss - Net Sales
Net Sales 1,716.29 Cr
in Mar 2025Figures in Cr
YoY Growth in year ended Mar 2025 is 32.48% vs 29.17% in Mar 2024
Profit And Loss - Operating Profit (PBDIT)
Operating Profit (PBDIT) 253.97 Cr
in Mar 2025Figures in Cr
YoY Growth in year ended Mar 2025 is 37.69% vs 11.71% in Mar 2024
Profit And Loss - Interest
Interest 1.46 Cr
in Mar 2025Figures in Cr
YoY Growth in year ended Mar 2025 is 21.67% vs 90.48% in Mar 2024
Profit And Loss - Profit After Tax
Profit After Tax 115.74 Cr
in Mar 2025Figures in Cr
YoY Growth in year ended Mar 2025 is -28.34% vs 62.66% in Mar 2024
